mammalian systems, HVC interneurons were inhibited by muscarine, and these effects were 48 reversed by atropine. Thus, cholinergic modulation reconfigures the HVC network in a more 49 complex fashion than implied by monolithic "gating". The two projection pathways are 50 decoupled through suppression of the inhibitory network that links them, while each is 51 simultaneously predominantly excited. We speculate that fluctuating cholinergic tone in HVC 52 could modulate the interaction of song motor commands with basal ganglia circuitry associated 53 with song perception and modification. Furthermore, if the in vitro distinction between RA-54 projecting neurons that we observed is also present in vivo, then the song system motor pathway 55 exhibits greater physiological diversity than has been commonly assumed. 
Electrophysiological recordings 124
For recording, slices were transferred to a superfusion chamber and perfused at 10-15 125 ml/min with ACSF maintained at 35°C. Anecdotally, our preliminary experiments indicated 126 improved tissue viability and stronger spontaneous synaptic activity in slices under these 127 conditions of elevated temperature. 128 Intracellular recordings were achieved using 'blind' whole cell recording techniques in 129 bridge mode. Borosilicate recording pipettes were pulled on a horizontal puller (Sutter 130 Instruments, Novato, CA) to a final resistance of 3-9 MΩ when filled with a pipette solution 131
consisting of: (in mM) 120 K-methylsulfate, 10 HEPES, 2 EGTA, 8 NaCl, 2 MgATP and 0.3 132 NaGTP. This solution was adjusted to pH 7.3 with KOH. A modified pipette solution was used 133 during some experiments (n = 36/169 cells): (in mM) 140 K-gluconate, 1 CaCl 2 , 10 HEPES, 10 134 EGTA, 2 MgCl 2 , and 4 Na 2 ATP. No differences in recordings were observed between these 135 solutions. Data were amplified and low pass filtered at 3 kHz with an NPI SEC-05 amplifier 136 (ALA Scientific, Westbury, NY). Data were acquired and analyzed using the Digidata 1320/ 137
PClamp8 package (Axon Instruments, Foster City, CA). Voltage traces were corrected for an 138 empirically measured liquid junction potential (+9 mV for standard ACSF and pipette solutions). 139
The cocktail of drugs used to block fast synaptic transmission was: 20 μM 6-cyano-7-140 nitroquinoxaline-2,3-dione (CNQX), 10 μM (R-(-)-3-(2-carboxypiperazin-4-141 yl)propanephosphonic acid) (CPP), and 10-20 μM (+)-bicuculline. At the concentration used, the 142 bicuculline free-base is not known to elicit the non-specific effects that have been reported 
Physiological measurement and analysis 155
Conventional whole-cell recordings are prone to rundown due to dialysis of the 156 intracellular contents. We were therefore vigilant in observing the baseline for stability. Only 157 cells that showed a stable membrane potential (V m ) below -50 mV, and that spiked readily to 158 current injection were considered for further analysis. During many recordings (n = 138/173), we 159 also monitored membrane resistance (R m ) with several brief (300 ms), small (20 and 80 pA) 160 hyperpolarizing current pulses. In those cases we also excluded the cell for analysis if, over the 161 baseline period, R m deviated by >15%. All but four cells remained within 10%. 162
The basic design for all experiments was to periodically make 500 ms depolarizing 163 current injections of a fixed amplitude and monitor Vm and evoked spike rate in an ongoing 164 fashion. (We changed the frequency of these measurements over the course of these studies.) 165
Once a stable baseline was established, drugs were bath applied as described and changes in Vm 166 and spike rate were assessed. For most cells (n = 164/173), resting Vm and the response to 167 current injection were measured every 10 s; a minority of cells (n = 9) were tested in the same 168 manner but more frequently. In all cases, the amplitude of the depolarizing current pulse was set 169 to roughly 20 -25% above AP threshold (mean: 250 ± 130 pA; range 50 -650 pA). 170
Physiological measurements for assessing cell types were taken from the first 6 sweeps 171 (typically the first minute of data; see Methods). The spike takeoff point was defined as the peak 172 of the second derivative of the voltage trace. Spike after hyperpolarization (AHP) amplitude and 173 time-to-peak (TTP) were measured relative to this point. AHP time-to-decay (TTD) was defined 174 as the time after the AHP peak for the voltage to decay halfway to baseline. The recovery slope 175 of the AHP was defined as the mean instantaneous slope for 2 ms following the peak of the AHP 176 (Spiro et al. 1999). Spike width was defined as the width halfway between the takeoff point and 177 the apex of the spike. Sag percentage was calculated from the response to hyperpolarizing 178 current pulse as [(ΔVm peak -ΔVm late )/(ΔVm peak )]*100%, where Vm peak is the initial peak voltage, 179
Vm late is the voltage at the end of the pulse, and Δ signifies the value's deviation from resting 180
Vm. Mean firing rate during depolarizing current pulses was normalized to the magnitude of the 181 injection as a measure of responsiveness (spikes/s/nA). The phasicness measure, ranging 182 between 0 and 1, was 1 minus a ratio calculated by the latency to the last spike over the total 183 duration of the pulse (for a graphical and algebraic representation see Supplementary Figure 1) . 184
This measure was chosen because it is simple, yet cleanly divided our cell distribution into two 185 disparate modes: completely accommodating phasic cells and minimally accommodating tonic 186
cells. 187
Mean V m and the rate of spiking to current injection were monitored in an ongoing 188 fashion during drug application and washout. Mean values for each parameter for the 10 sweeps 189 just prior to drug application were taken as the pre-drug value, and the mean for the last 10 190 sweeps of drug application were taken as the post-drug value. For individual drug presentations, 191 the significance of a given drug effect was also assessed with an unpaired t test comparison of 192 the 10 pre-drug and post-drug values, and a significant effect implies p < 0.05. Population 193 measures for drug applications were assessed with a paired t test. 
Assessing cholinergic modulation of classes of HVC neurons 320
We identified four different physiological classes of HVC neurons in vitro, and a panel of 321 intrinsic property measurements for each of these classes is reported in Table 1 . We assessed 322 whether these neurons are sensitive to modulation by cholinergic drugs and whether this 323 sensitivity varied as a function of cell class. To do this, we made whole cell recordings from 324 HVC in vitro under current clamp conditions. Periodically (see Methods) we measured resting 325 V m and the spiking response to a single 500 ms depolarizing current pulse. The amplitude of the 326 current pulse was adjusted to roughly 20 -25% above threshold and fixed for the duration of the 327 experiment. 328
If baseline behavior was stable (see Methods), drugs were applied and we continued to 329 monitor changes in resting V m and spike rate. The effects of muscarinic cholinergic receptor 330 activation were assessed with application of the cholinergic agonists muscarine (10 µM) and 331 carbachol (10 or 100 µM). In some experiments, to assess the selectivity of the observed effects 332 for muscarinic receptors, we added the selective muscarinic receptor antagonist atropine (1 µM) 333 to the bath in the continued presence of muscarine. Additionally, to assess the network 334 dependence of drug effect, some experiments were performed in the presence of a cocktail of 335 drugs that block fast excitatory and inhibitory synaptic transmission (see Methods). In many 336 cases, we also measured the dynamics of input resistance (Supplementary Figure 4) . Because 337 assessing nicotinic cholinergic modulation is complicated by rapid receptor desensitization, we 338 did not attempt to evaluate the contribution of nicotinic receptors to cholinergic modulation 339 using our bath perfusion approach. 340 341
Cholinergic agonists excite phasic HVC-RAn 342
We tested fourteen phasic type RA-projecting cells with cholinergic drugs in the manner 343 described above, and we observed a consistent, robust, and direct excitation following 344 application of muscarine, a selective agonist for muscarinic type cholinergic receptors. Phasic 345 HVC-RAn showed increases in evoked spike rate and depolarization of resting Vm following 346 muscarine application. These effects were reversed by the selective muscarinic receptor 347 antagonist atropine, and persisted in the presence of fast synaptic blockers. Figure 3A depicts a 348 typical experiment. For this cell we continuously measured resting membrane potential and 349 spike rate evoked by a somatic current injection pulse (+0.13 nA). These measures were stable 350 prior to drug application, and this stability continued when a cocktail of fast synaptic 351 transmission blockers (CNQX, CPP, bicuculline; see Methods) was applied and then maintained 352 for the duration of the recording. When 10 uM muscarine was applied to the bath, the cell 353 exhibited an abrupt increase in evoked spike rate and a sharp membrane depolarization. These 354 effects rapidly reversed upon bath application of 1 µM atropine in the continued presence of 355 agonist. Subsequently, baseline spiking behavior reemerged and the cell repolarized to near its 356 initial value. 357
Eleven phasic HVC-RAn were treated with 10 μM muscarine alone, and all were 358 robustly excited by the drug. For the 11 cells treated with muscarine, comparing the last ten 359 sweeps before wash-in and the last ten sweeps before washout (see Methods), each cell showed 360 significantly greater spiking and 10/11 also showed a significant depolarization. As a 361 population, these cells showed significant increases in evoked spike rate (pre: 5.20 ± 4.9 362 spikes/s; post: 21.5 ± 12 spikes/s; paired t test, p < 0.01) and membrane voltage (pre: -73.9 ± 13 363 mV; post: -65.9 ± 14 mV; paired t test, p < 0.01) ( Figure 3B,C) . Four of the neurons fired so 364 vigorously after muscarine wash-in that spike failure was seen (e.g. Supplementary Figure 5) . 365 We did not discern whether this is a primary effect of muscarine or whether the mere 366 depolarization by muscarine secondarily causes the spike failure, however cells that showed 367 spike failure did not differ form the others in the magnitude of depolarization. Despite the 368 dramatic excitation elicited by muscarine, no phasic HVC-RAn ever fired spikes at rest under 369 any condition. 370
The excitatory effects of muscarine on phasic HVC-RAn did not depend on synaptic 371 network interactions. In an additional set of experiments (n = 5), 10 μM muscarine was applied 372
in the presence of a cocktail of synaptic blockers (see Methods) and all five cells showed 373 significant increases in evoked spiking and membrane potential. Significant population changes 374 were comparable to those seen without synaptic blockers for mean evoked spike rate (pre: 1.36 ± 375 1.3 spikes/s; post: 17.8 ± 9.0 spikes/s; paired t test, p < 0.05) and membrane voltage (pre: -73.5 ± 376 8.2 mV; post: -67.2 ± 8.2 mV; paired t test, p < 0.01) ( Figure 3B,C) . These data are consistent 377 with a direct effect of muscarine on these neurons ( Figure 3B,C) . 378
The effects of muscarine on phasic HVC-RAn were consistently reversed by atropine, a 379 competitive antagonist for muscarinic receptors, further supporting a specific action at 380 muscarinic cholinergic receptors. Some cells treated with muscarine were also subsequently 381 perfused with 1 μM atropine in the continued presence of muscarine. In each of seven cases, the 382 effects of muscarine on spiking and V m were significantly reversed upon wash-in of atropine. 383
Spiking behavior in all seven cells was increased by the initial muscarine application, and 384 atropine subsequently significantly decreased spiking in each cell. Six cells were also 385 depolarized by muscarine initially, and all were significantly hyperpolarized when treated with 386 atropine. Population mean spiking following this treatment was significantly decreased from 387 23.0 ± 11 spikes/s to 8.30 ± 9.6 spikes/s (n = 7; paired t test, p < 0.01) ( Figure 3B ). Population 388 mean membrane voltage was also significantly hyperpolarized (n = 7; pre: -57.7 ± 9.7 mV; post: 389 -61.9 ± 9.1 mV; paired t test, p < 0.05) ( Figure 3C ). These changes cannot be explained by 390 desensitization of receptors; when presented alone, muscarine was in the bath with sustained 391 effects for substantially longer (mean = 270 ± 74 s across all cell types) than the latency to 392 atropine addition (mean = 170 ± 50 s across all cell types). 393
Although we collected substantial anatomical and intrinsic physiological data indicating 394 that the HVC-RAn pathway includes a population of tonically firing cells in addition to these 395 phasic cells, we had difficulty obtaining stable and consistent data from them in the presence of 396 cholinergic drugs. Therefore we do not report their response to cholinergic stimulation here. 397 398
Cholinergic agonists excite basal ganglia-projecting HVC neurons 399
We also assessed cholinergic modulation in HVC neurons projecting to the basal ganglia 400 nucleus Area X (HVC-Xn) by performing a very similar set of experiments. These cells were 401 also repeatedly injected with brief pulses of suprathreshold depolarizing current, and the evoked 402 spike rate and resting membrane potential were measured on an ongoing basis. Like phasic 403 HVC-RAn, HVC-Xn were excited by muscarinic cholinergic activation albeit with somewhat 404 lower consistency, typically showing increases in evoked spike rate and depolarization of their 405 resting membrane potential after bath application of muscarine. These effects also persisted in 406 the presence of blockers of fast synaptic transmission and were reversed by adding atropine to 407 the bath in the presence of muscarine. An example of all of these effects can be seen in Figure  408 4B. Resting membrane potential and spiking evoked by pulses of current injection (+0.16 nA) 409 were continuously measured every 10 s. These measures were at baseline and after addition of 410 fast synaptic transmission blockers. Upon addition of 10 μM muscarine to the bath, the cell 411 rapidly depolarized > 10 mV and nearly doubled its spike rate in response to current injection. 412
These effects were significantly reversed when 1 µM atropine was applied in the continued 413 presence of agonist. 414
Given the fact that our analysis of projection class and physiological properties did not 415 allow a completely unambiguous separation of HVC-Xn and tonic-firing RA projecting HVC 416 neurons, here we first restricted our dataset to anatomically identified HVC-Xn. A total of ten 417
identified HVC-Xn were tested with 10 μM bath applied muscarine. Of these cells, most (9/10) 418 were significantly depolarized by the drug and six additionally showed a significant increase in 419 spiking. One exceptional cell showed a dramatic effect that was consistently of the opposite 420 sign, exhibiting significant decreases in both spiking and membrane potential. When this cell is 421 included with the other data, filled HVC-Xn still showed a significant depolarization (pre: -64.7 422 ± 7.8 mV to -57.4 ± 12 mV; paired t test, p < 0.01), however the change in spike rate was not 423 significant (pre: 14.2 ± 6.2 spikes/s; post: 18.3 ± 11 spikes/s; paired t test, p = 0.17) (Figure  424 4C,D). When the outlier is excluded, the remaining cells (n = 9) showed significant changes in 425 both measures (paired t test, p < 0.05). An example of typical muscarine effects on an 426
anatomically identified HVC-Xn is shown in Figure 4A . At baseline and after adding fast 427 synaptic blockers to the bath, this cell showed steady tonic spiking in response to somatic current 428 injection. Bath application of 10 μM muscarine evoked a significant increase in this tonic firing 429 rate and also significantly depolarized the cell. HVC-Xn were observed in fast synaptic blockers. Over all cells (n = 6) there was a significant 452 membrane depolarization from -62.7 ± 9.1 mV to -55.3 ± 9.8 (paired t test, p < 0.05), however 453 again due to the bimodal distribution of effects, mean spiking was not significantly changed (pre: 454 12.0 ± 6.3 spikes/s to 16.6 ± 11; paired t test, p = 0.23) (Figure 4C,D) . Changes in both 455 measures were significant for the five excited cells (paired t test; p < 0.05). 456
Further confirming the cholinergic modulation of HVC-Xn, very similar predominantly 457 excitatory effects were observed in thirteen putative HVC-Xn that were tested with carbachol, an 458 unselective cholinergic receptor agonist. Nine cells were treated with 10 μM (n = 3) or 100 μM 459 (n = 6) carbachol (similar effects were seen with both concentrations and these were combined 460 for analysis). In addition, five neurons were treated with 100 μM carbachol in the presence of 461 synaptic blockers. Among all carbachol experiments, 13/14 (including all five with synaptic 462 blockers) showed a significant depolarization and a significant increase in spiking in response to 463 current injection, suggesting direct, predominantly excitatory effects of carbachol on the 464 recorded neuron. The exceptional neuron (tested with carbachol alone) showed a strong and 465 significant decrease in spikes to current injection that resembled the occasional inhibitory effects 466 of muscarine. Overall, the population mean spike rate was significantly increased from 12.0 ± 467 4.0 spikes/s to 19.7 ± 8.1 spikes/s (paired t test, p < 0.001) and the population mean membrane 468 voltage was elevated from -64.5 ± 8.6 mV to -57.1 ± 9.6 mV by carbachol application (paired t 469 test, p < 0.001) (Figure 4C,D) . 470
The effects of muscarine on HVC-Xn were reversed by atropine, consistent with a 471 specific action at muscarinic cholinergic receptors. Nine cells tested with muscarine were 472 additionally subsequently perfused with 1 μM atropine in the continued presence of muscarine, 473 leading to a reversal of the initial effects. The robust and significant depolarization and increase 474 in spikes evoked by current injection that appeared shortly after addition of muscarine to the bath 475 abruptly and nearly completely reversed when 1 μM atropine was added in the continued 476 presence of muscarine. Upon addition of atropine, all cells showed a significant change in 477 membrane potential that was opposite in sign to the primary effects of muscarine. This was also 478 true with respect to firing rate changes for 8/9 cells. Considering the cells that were initially 479 excited by muscarine (n = 8/9), population mean spike rate was significantly reduced by atropine 480 (n = 8; pre: 18.4 ± 8.8 spikes/s; post: 8.15 ± 7.2 spikes/s; paired t test, p < 0.001), and the 481 population mean membrane voltage was also significantly lower following atropine application 482 (n = 8; pre: -56.5 ± 8.7 mV; post: -60.2 ± 9.3 mV; paired t test, p < 0.01) (Figure 4C,D) . The 483 ninth cell tested with atropine was initially inhibited by muscarine, and this effect was also 484 reversed by atropine; the cell exhibited significantly more spiking and a significantly more 485 depolarized membrane potential following atropine addition. A typical example of the atropine 486 reversal of muscarine effects is depicted in the latter time points of Figure 4B . continuously monitoring the evoked spike rate and resting membrane potential. In contrast to the 495 muscarine effects on projection neurons seen in these experiments, we observed strong inhibition 496 of interneurons following application of muscarine, which was reversed by atropine. One 497 example showing both effects is depicted in Figure 5A . Prior to drug application, this HVC-In 498 cell showed tonic high-frequency firing in response to current injection. Shortly after bath 499 application of 10 µM muscarine, there was a large, sudden hyperpolarization, accompanied by 500 complete cessation of spiking. Subsequently, after addition of 1 µM atropine there was a 501 complete recovery of baseline physiology, with the membrane potential and spike rate ultimately 502 stably returning to their initial values. 503
Fourteen HVC-In were tested with 10 μM muscarine and most were dramatically 504 inhibited. Of the 14 cells, 13 showed a significant decrease in spike rate to current injection, and 505 12 were significantly hyperpolarized after muscarine wash-in. Considering pre and post drug 506
population mean values for all muscarine applications (n = 14), spiking to current injection was 507 significantly reduced (pre: 46.0 ± 27 spikes/s; post: 17.2 ± 18 spikes/s; paired t test, p < 0.001) 508
and membrane voltage was significantly hyperpolarized (pre: -63.8 ± 10 mV; post: -68.3 ± 11 509 mV; paired t test, p < 0.01) ( Figure 5B,C). We were not able to test the effect of muscarine on 510 HVC-In under conditions of fast synaptic blockade. 511
The inhibition of HVC-In by muscarine was also consistently reversed by atropine. Six 512 neurons that were inhibited by muscarine initially were subsequently treated with atropine in the 513 continued presence of muscarine. Each of these cells was initially inhibited by muscarine; all of 514 them were significantly depolarized when atropine was added, and 5/6 showed a significant 515 increase in spikes to current injection. Population mean membrane voltage was significantly 516 increased from -70.0 ± 14 mV to -60.5 ± 14 mV (n = 6; paired t test, p < 0.01) after atropine 517 wash-in ( Figure 5C ). Population mean spiking was also significantly increased (n = 6; pre: 20.4 518 ± 9.0 spikes; post: 36.6 ± 12 spikes; paired t test, p < 0.05) ( Figure 5B carb.
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